{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T04:04:25Z","timestamp":1770005065489,"version":"3.49.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Historically, secondary amyloidosis has been a feared complication of chronic inflammatory conditions. The fibril protein AA derives from the acute phase reactant serum amyloid A (SAA). Long-term elevation of SAA levels remains a major risk factor for the development of AA amyloidosis in rheumatic diseases, and the prognosis may be unpredictable. Nowadays, with increased availability of effective biological agents, the incidence of AA amyloidosis seems to be declining. Still, genetically predisposed subjects with slowly progressive disease and mild symptoms combined with ongoing systemic inflammation may be at risk. Interleukin-6 (IL-6) is one of the drivers of SAA release and effectiveness of the humanized anti-IL-6 receptor antibody tocilizumab (TCZ) for the treatment of AA amyloidosis has been observed in some rheumatic conditions. Herein, we report two male subjects with longstanding ankylosing spondylitis (AS) complicated by renal amyloidosis who received TCZ with rapid and beneficial effects regarding inflammation and proteinuria. To the best of our knowledge, the use of TCZ in AS patients with this extra-articular manifestation has not previously been described. The paper includes histopathology, clinical follow-up, and longitudinal data of the two cases along with a comprehensive review of relevant literature. Mechanisms behind amyloid-mediated tissue damage and organ dysfunction are discussed. Altogether, our data highlight that blocking IL-6 signaling may represent a promising therapeutic option in patients with renal AA amyloidosis.<\/jats:p>","DOI":"10.3389\/fmed.2021.661101","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T04:45:31Z","timestamp":1619412331000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Successful Treatment of AA Amyloidosis in Ankylosing Spondylitis Using Tocilizumab: Report of Two Cases and Review of the Literature"],"prefix":"10.3389","volume":"8","author":[{"given":"Per","family":"Eriksson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"M\u00f6lne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Wirestam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Sj\u00f6wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0272-6386(95)90647-9","article-title":"Treatment of amyloidosis","volume":"26","author":"Tan","year":"1995","journal-title":"Am J Kidney Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000506696","article-title":"The pathology of amyloidosis in classification: a review","volume":"143","author":"Picken","year":"2020","journal-title":"Acta Haematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/jcp.22.4.410","article-title":"An evaluation of current methods for the diagnostic histochemistry of amyloid","volume":"22","author":"Cooper","year":"1969","journal-title":"J Clin Pathol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1016\/j.febslet.2009.04.026","article-title":"Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis","volume":"583","author":"Westermark","year":"2009","journal-title":"FEBS Lett."},{"key":"B5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1258\/acb.2011.011225","article-title":"Amyloidosis","volume":"49","author":"Pinney","year":"2012","journal-title":"Ann Clin Biochem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jaut.2004.02.003","article-title":"Reduced anti-TNF\u03b1 autoantibody levels coincide with flare in systemic lupus erythematosus","volume":"22","author":"Sj\u00f6wall","year":"2004","journal-title":"J Autoimmun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"622326","DOI":"10.3389\/fimmu.2020.622326","article-title":"C-reactive protein levels in systemic lupus erythematosus are modulated by the interferon gene signature and CRP gene polymorphism rs1205","volume":"11","author":"Enocsson","year":"2021","journal-title":"Front Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1002\/art.11163","article-title":"Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy","volume":"48","author":"Gottenberg","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B9","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.amjmed.2005.01.028","article-title":"Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists","volume":"118","author":"Fern\u00e1ndez-Nebro","year":"2005","journal-title":"Am J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e7859","DOI":"10.1097\/MD.0000000000007859","article-title":"Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study","volume":"96","author":"Esatoglu","year":"2017","journal-title":"Medicine."},{"key":"B11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s10157-016-1271-y","article-title":"Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience","volume":"21","author":"Ozawa","year":"2017","journal-title":"Clin Exp Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1681\/ASN.2006050460","article-title":"Amyloidosis-associated kidney disease","volume":"17","author":"Dember","year":"2006","journal-title":"J Am Soc Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/76216","article-title":"Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis","volume":"6","author":"Yan","year":"2000","journal-title":"Nat Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1053\/ajkd.1998.v31.pm9631837","article-title":"Familial amyloid polyneuropathy type I (Portuguese): distribution and characterization of renal amyloid deposits","volume":"31","author":"Lobato","year":"1998","journal-title":"Am J Kidney Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1093\/ndt\/gfh063","article-title":"Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation","volume":"19","author":"Snanoudj","year":"2004","journal-title":"Nephrol Dial Transplant."},{"key":"B16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0272-6386(89)80041-1","article-title":"Resolution of nephrotic syndrome and lack of progression of heroin-associated renal amyloidosis","volume":"13","author":"Crowley","year":"1989","journal-title":"Am J Kidney Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1471-2369-13-118","article-title":"Significant association between renal function and amyloid-positive area in renal biopsy specimens in AL amyloidosis","volume":"13","author":"Kuroda","year":"2012","journal-title":"BMC Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/13506129.2017.1338565","article-title":"Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in both AA amyloidosis associated with rheumatoid arthritis and AL amyloidosis","volume":"24","author":"Kuroda","year":"2017","journal-title":"Amyloid."},{"key":"B19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/14397595.2018.1515145","article-title":"AA amyloidosis - Benefits and prospects of IL-6 inhibitors","volume":"29","author":"Okuda","year":"2019","journal-title":"Mod Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3109\/13506129.2014.1002031","article-title":"AA amyloidosis treated with tocilizumab: case series and updated literature review","volume":"22","author":"Courties","year":"2015","journal-title":"Amyloid."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.2169\/internalmedicine.1099-18","article-title":"First nationwide survey of 199 patients with amyloid A amyloidosis in Japan","volume":"57","author":"Okuda","year":"2018","journal-title":"Intern Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1093\/ndt\/gfq831","article-title":"Renal amyloidosis revisited: amyloid distribution, dynamics and biochemical type","volume":"26","author":"Hopfer","year":"2011","journal-title":"Nephrol Dial Transplant."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000444206","article-title":"The prevalence and management of systemic amyloidosis in Western Countries","volume":"2","author":"Nienhuis","year":"2016","journal-title":"Kidney Dis (Basel)."},{"key":"B24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/13506129.2017.1342235","article-title":"Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre","volume":"24","author":"Lane","year":"2017","journal-title":"Amyloid."},{"key":"B25","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1186\/1471-2458-12-974","article-title":"Incidence and survival in non-hereditary amyloidosis in Sweden","volume":"12","author":"Hemminki","year":"2012","journal-title":"BMC Public Health."},{"key":"B26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bjh.12286","article-title":"Systemic amyloidosis in England: an epidemiological study","volume":"161","author":"Pinney","year":"2013","journal-title":"Br J Haematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.rceng.2012.09.001","article-title":"Clinical characteristics of the patients with systemic amyloidosis in 2000-2010","volume":"213","author":"Real de As\u00faa","year":"2013","journal-title":"Rev Clin Esp (Barc)."},{"key":"B28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13075-015-0627-0","article-title":"The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study","volume":"17","author":"Exarchou","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/acr.22176","article-title":"Estimating the occurrence of renal complications among persons with ankylosing spondylitis","volume":"66","author":"Levy","year":"2014","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s00296-012-2646-3","article-title":"Secondary amyloidosis in ankylosing spondylitis","volume":"33","author":"D\u00f6nmez","year":"2013","journal-title":"Rheumatol Int."},{"key":"B31","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1136\/ard.52.3.174","article-title":"Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis","volume":"52","author":"Lehtinen","year":"1993","journal-title":"Ann Rheum Dis."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew349","article-title":"New treatment targets for axial spondyloarthritis","author":"Sieper","year":"2016","journal-title":"Rheumatology (Oxford)."},{"key":"B34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13023-017-0642-0","article-title":"Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever","volume":"12","author":"Ugurlu","year":"2017","journal-title":"Orphanet J Rare Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/cei.12234","article-title":"Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis","volume":"175","author":"Migita","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/jcph.1375","article-title":"Characterization of the effect of renal impairment on upadacitinib pharmacokinetics","volume":"59","author":"Mohamed","year":"2019","journal-title":"J Clin Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"591176","DOI":"10.3389\/fimmu.2020.591176","article-title":"Impact of Janus Kinase Inhibition on the treatment of axial spondyloarthropathies","volume":"11","author":"Hammitzsch","year":"2020","journal-title":"Front Immunol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.661101\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T04:45:34Z","timestamp":1619412334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.661101\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":37,"alternative-id":["10.3389\/fmed.2021.661101"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.661101","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"article-number":"661101"}}